Suppr超能文献

评估肉毒杆菌毒素治疗腋窝多汗症的有效性及生活质量:一项为期一年的前瞻性研究。

Assessing Botulinum Toxin Effectiveness and Quality of Life in Axillary Hyperhidrosis: A One-Year Prospective Study.

作者信息

Castiglione Luca, Murariu Marius, Boeriu Estera, Enatescu Ileana

机构信息

Doctoral School, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.

Department of General Surgery, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.

出版信息

Diseases. 2024 Jan 3;12(1):15. doi: 10.3390/diseases12010015.

Abstract

This study hypothesized that botulinum toxin (Botox) therapy would sustainably reduce sweat production in axillary hyperhidrosis patients over one year and significantly improve various quality-of-life aspects, including psychological well-being, social interactions, and daily functioning. The objectives were to quantitatively measure changes in sweat production and qualitatively assess the evolving impact on patients' quality of life over one year. Conducted prospectively at the Pius Brinzeu Clinical Emergency Hospital in Timisoara, Romania, this study complied with ethical standards and included adults with primary axillary hyperhidrosis unresponsive to conventional treatments. Participants underwent Botox injections and were evaluated at baseline, six months, and one year, using the Hyperhidrosis Disease Severity Scale (HDSS), WHOQOL-BREF, and the Dermatology Life Quality Index (DLQI), among other tools. Involving 81 patients, the study showed significant improvements in sweat production and quality-of-life metrics. Sweat production decreased from 0.81 g to 0.23 g per 15 min over one year ( < 0.001). HDSS scores reduced from 3.4 to 1.5, indicating a decrease in symptom severity ( < 0.001). The DLQI total score, assessing life quality impact, notably dropped from 19.9 to 6.9 ( < 0.001). Quality-of-life domains also showed significant improvements, especially in the social (from 65.3 to 73.4, < 0.001) and environmental aspects (from 68.0 to 72.1, < 0.001). Higher HDSS and sweat production were significantly associated with a lower quality of life on the DLQI (B coefficients of -4.1 and -2.5, respectively). Botulinum toxin therapy proved effective in reducing sweat production and improving the quality of life in axillary hyperhidrosis patients over a one-year period. These improvements were statistically significant in both physical and psychosocial domains. The study highlights the potential long-term benefits of Botox therapy for hyperhidrosis.

摘要

本研究假设,肉毒杆菌毒素(保妥适)疗法能在一年内持续减少腋窝多汗症患者的汗液分泌,并显著改善包括心理健康、社交互动和日常功能等多个生活质量方面。其目标是定量测量汗液分泌的变化,并定性评估一年内对患者生活质量的演变影响。本研究在罗马尼亚蒂米什瓦拉的皮乌斯·布林泽乌临床急诊医院前瞻性开展,符合伦理标准,纳入了对传统治疗无反应的原发性腋窝多汗症成人患者。参与者接受了肉毒杆菌毒素注射,并在基线、六个月和一年时使用多汗症疾病严重程度量表(HDSS)、世界卫生组织生活质量简表(WHOQOL - BREF)和皮肤病生活质量指数(DLQI)等工具进行评估。该研究涉及81名患者,结果显示汗液分泌和生活质量指标有显著改善。一年内,每15分钟的汗液分泌量从0.81克降至0.23克(<0.001)。HDSS评分从3.4降至1.5,表明症状严重程度降低(<0.001)。评估生活质量影响的DLQI总分显著从19.9降至6.9(<0.001)。生活质量领域也有显著改善,尤其是在社交方面(从65.3提高到73.4,<0.001)和环境方面(从68.0提高到72.1,<0.001)。较高的HDSS和汗液分泌与DLQI较低的生活质量显著相关(B系数分别为 - 4.1和 - 2.5)。肉毒杆菌毒素疗法被证明在一年内有效减少腋窝多汗症患者的汗液分泌并改善生活质量。这些改善在身体和心理社会领域均具有统计学意义。该研究突出了保妥适疗法治疗多汗症的潜在长期益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/10814778/bf89a7289501/diseases-12-00015-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验